trocordis 125 mg filmsko obložene tablete
actavis group ptc ehf. - bosentan - filmsko obložena tableta - bosentan 125 mg / 1 tableta - bosentan
maxalt 10 mg peroralni liofilizat
merck sharp & dohme, d.o.o. - rizatriptan - peroralni liofilizat - rizatriptan 10 mg / 1 prašek - rizatriptan
maxalt 5 mg peroralni liofilizat
merck sharp & dohme, d.o.o. - rizatriptan - peroralni liofilizat - rizatriptan 5 mg / 1 prašek - rizatriptan
ibuprofen farmalider 20 mg/ml peroralna suspenzija
farmalider s.a. - ibuprofen - peroralna suspenzija - ibuprofen 20 mg / 1 ml - ibuprofen
ibuprofen farmalider 20 mg/ml peroralna suspenzija
farmalider s.a. - ibuprofen - peroralna suspenzija - ibuprofen 20 mg / 1 ml - ibuprofen
cerdelga
sanofi b.v. - eliglustat - gaucher bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - cerdelga je indicirano za dolgotrajno zdravljenje odraslih bolnikov s gaucher boleznijo tipa 1 (gd1), ki so slabo metabolisers cyp2d6 (pms), vmesni metabolisers (ims) ali obsežne metabolisers (ems).
tysabri
biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
voxzogo
biomarin international limited - vosoritide - achondroplasia - zdravila za zdravljenje bolezni kosti - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.